Notes
neutral protamine Hagedorn
proportion of glycoslyated haemoglobin
Reference
PAWASKAR M, et al. Modeling Long-Term Cost-Effectiveness of Sitagliptin and SGLT2i Combination Therapy for the Treatment of Type 2 Diabetes. 78th Annual Scientific Sessions of the American Diabetes Association : abstr. 1247-P, 22 Jun 2018. Available from: URL: https://plan.core-apps.com/tristar_ada18/abstract/807d2f9885450670bb994661e36238df
Rights and permissions
About this article
Cite this article
Sitagliptin plus SGLT2i cost effective in UK. PharmacoEcon Outcomes News 808, 27 (2018). https://doi.org/10.1007/s40274-018-5142-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5142-5